Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures

2000446 citationsJournal Article

Authors

Simon Shorvon · National Hospital for Neurology and Neurosurgery

Armand Löwenthal · ZNA Middelheim Hospital

Diéter Janz · Humboldt-Universität zu Berlin

E Bieleń · UCB Pharma (Belgium)

P Loiseau · Université de Bordeaux

for the European Levetiracetam Study Group · University College London

Abstract

The antiepileptic efficacy and tolerability of LEV (1,000 mg/d and 2,000 mg/d, administered in two divided doses) as add-on therapy was established in patients with refractory partial seizures in this clinical study.

Topics & Keywords

Epilepsy research and treatment Pharmacological Effects and Toxicity Studies Neuroscience and Neuropharmacology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Epilepsia

Volume 41, Issue 9, pp. 1179-1186

DOI: 10.1111/j.1528-1157.2000.tb00323.x

Field-Weighted Citation Impact: 19.02